Market Overview

Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue

Mylan Laboratories (NASDAQ: MYL) announces its next round of earnings this Wednesday, October 26, 2011. Get the latest predictions in Benzinga's essential guide to the company's third quarter earnings report.

Earnings and Revenue:

Analysts are predicting an EPS reading of 51 cents/share and revenues of $1.54 billion. Mylan Laboratories' latest numbers will no doubt be compared with the company's year-ago quarter, when it reported a profit of 43 cents/share on revenues of $1.36 billion. Can Mylan Laboratories manage the estimated 18.6% rise in EPS and 13.2% increase in revenues from the year-ago quarter as analysts are predicting? We'll have to wait until Wednesday to find out.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter Q2 Q1 Q4 Q3
EPS Estimate $0.45 $0.44 $0.45 $0.42
EPS Actual $0.52 $0.44 $0.45 $0.43

Stock Performance:

As of October 20, 2011, Mylan Laboratories' current share price was $17.38. Since January 1st, shares of Mylan Laboratories have declined 17.7%. For a full 12 months, the return has declined by 14.2%. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

  • Long-term shareholders are already wary of 12-month losses prior to the announcement

Average Stock Rating:

The average rating by analysts for Mylan Laboratories is a Moderate Buy. This rating hasn't budged over the past three months.

Competitors:

Want to check out the performance of Mylan Laboratories closest competitors? Take a look at some of the company's peers in the healthcare sector.

  • Forest Laboratories (NYSE: FRX): Hold with a $0.91 recent quarter EPS
  • Impax Laboratories (NASDAQ: IPXL): Hold with a $0.19 recent quarter EPS
  • Merck & (NYSE: MRK): Moderate Buy with a $0.95 recent quarter EPS
  • Lannett Company (LCI): Strong Buy with a -$0.07 recent quarter EPS

Mylan Laboratories is in the medicine-generic drugs industry, which has experienced price/earnings growth of 1.1%.

Finally, a description of the company's main areas of operation: Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets, and distributes pharmaceuticals and active pharmaceutical ingredients.

Take Action:

Now that you have reviewed all the numbers, be ready to move if the upcoming Mylan Laboratories earnings report has any surprises. Also, come back to Benzinga after the announcement for a full recap and a guide to your next steps.

  • To see up-to-date news on Mylan Laboratories, click here
  • To see other trading ideas, click here
  • To see other company earnings recaps, click here

Posted-In: Earnings Long Ideas News Short Ideas Previews Trading Ideas

 

Related Articles (IPXL + FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters